Table 1. invasive scrotal cancers by country, year of/age at diagnosis, histological category, HPV DNA detection and genotyping by 4 assays, HPV histological localization by LCM, HPV16 E6*I mRNA detection, p16^INK4a and p53 overexpression.

	Cases studied
	1	2	3	4	5	6
Country of origin	Spain	Spain	Australia	Australia	Nigeria	Nigeria
Year of diagnosis	2003	2008	2002	2007	2007	2015
Age at diagnosis	71	62	59	46	42	66
Histological diagnosis	Usual SCC	Usual SCC	Warty SCC	Usual SCC	Basaloid SCC	Basaloid SCC
HPV DNA and RNA analysis
SPF₁₀⁻DEIA-LiPA₂₅	HPV negative	HPV negative	HPV16	HPV negative	HPV 16	HPV 16
MPTS123-PCR Luminex	HPV negative	HPV negative	HPV 16	HPV negative	HPV 16	HPV 16
Beta HPVs assay	HPV negative	HPV negative	HPV negative	HPV negative	HPV negative	HPV negative
Cutaneous Wart-Associated HPVs	HPV negative	HPV negative	HPV negative	HPV negative	HPV negative	HPV negative
HPV16 E6*I mRNA-Luminex	HPV negative	HPV negative	Positive	HPV negative	Positive	Positive
DNA and RNA quality control	Positive	Positive	Positive	Positive	Positive	Positive
Laser capture microdissection
Localization of HPV	n.a.	n.a.	SCC	n.a.	SCC	SCC
Immunohistochemistry analysis in primary cancer cells
p16^INK4a overexpression	<5%	25%	>75%	<5%	>75%	>75%
p53 overexpression	>75%	<25%	<25%	>75%	<25%	<25%a

Abbreviations: −=negative; SCC=well differentiated squamous cell carcinoma; n.a.=not applicable.

Poor slide quality made difficult the analyses.

Table 1. invasive scrotal cancers by country, year of/age at diagnosis, histological category, HPV DNA detection and genotyping by 4 assays, HPV histological localization by LCM, HPV16 E6*I mRNA detection, p16INK4a and p53 overexpression.